

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/643,141		ATTY. DOCKET NO.: C1037.70049US00	
				FILING DATE: August 18, 2003		CONFIRMATION NO.: 3287	
				APPLICANT: Hutcherson et al.			
				GROUP ART UNIT: 1643		EXAMINER: Anne Gussow	
Sheet	1	of	2				

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/AMG/		5,663,153		Hutcherson et al.	09-02-1997
↓		5,723,335		Hutcherson et al.	03-03-1998
↓		6,194,388	B1	Krieg et al.	02-27-2001
↓		6,207,646	B1	Krieg et al.	03-27-2001
↓		7,223,741	B2	Krieg	05-29-2007
↓		2002-0165178	A1	Schetter et al	11-07-2002
/AMG/		2008-0009455	A9	Krieg et al.	01-10-2008

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/AMG/		BARKER et al., Inhibition of Plasmodium falciparum malaria using antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):514-8.	
↓		BENNETT et al., Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol. 1994 Apr 1;152(7):3530-40.	
↓		BROWN et al., Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem. 1994 Oct 28;269(43):26801-5.	
↓		COULSON et al., A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells. Mol Pharmacol. 1996 Aug;50(2):314-25.	
↓		FENNEWALD et al., Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J Biol Chem. 1995 Sep 15;270(37):21718-21.	
↓		GALBRAITH et al., Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev. 1994 Fall;4(3):201-6.	
↓		KHALED et al., Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1996 Feb 15;24(4):737-45.	
/AMG/		PEREZ et al., Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5957-61.	

EXAMINER: /Anne M. Gussow/	DATE CONSIDERED: 11/02/2008
-----------------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/643,141		ATTY. DOCKET NO.: C1037.70049US00	
				FILING DATE: August 18, 2003		CONFIRMATION NO.: 3287	
				APPLICANT: Hutcherson et al.			
				GROUP ART UNIT: 1643		EXAMINER: Anne Gussow	
Sheet	2	of	2				

/AMG/		STEIN et al., Phosphorothioate oligodeoxynucleotides--anti-sense inhibitors of gene expression? Pharmacol Ther. 1991 Dec;52(3):365-84.	
/AMG/		STOREY et al., Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res. 1991 Aug 11;19(15):4109-14.	
/AMG/		WANG et al., Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides. J Clin Invest. 1996 Jul 15;98(2):443-50.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /Anne M. Gussow/	DATE CONSIDERED: 11/02/2008
-----------------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.